AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ProthenaProtagonist TherapeuticsSatsuma PharmaceuticalsSyros PharmaceuticalsCatalyst Pharmaceuticals
SymbolNASDAQ:PRTANASDAQ:PTGXNASDAQ:STSANASDAQ:SYRSNASDAQ:CPRX
Price Information
Current Price$10.70$18.64$25.96$12.00$5.08
52 Week RangeBuyBuyBuyBuyBuy
Beat the Market™ Rank
Overall Score1.61.51.71.22.0
Analysis Score3.43.53.52.43.5
Community Score2.82.22.42.63.0
Dividend Score0.00.00.00.00.0
Ownership Score1.01.02.01.01.0
Earnings & Valuation Score0.60.60.60.02.5
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$17.33$30.60$33.00$13.29$9.50
% Upside from Price Target61.99% upside64.16% upside27.12% upside10.71% upside87.01% upside
Trade Information
Market Cap$426.25 million$495.47 million$488.30 million$524.10 million$526.41 million
Beta1.851.41N/A1.631.95
Average Volume248,312616,71460,283316,6802,012,438
Sales & Book Value
Annual Revenue$810,000.00$230,000.00N/A$1.98 million$102.31 million
Price / Sales527.222,223.43N/A276.935.13
CashflowN/AN/AN/AN/A$0.32 per share
Price / CashN/AN/AN/AN/A15.69
Book Value$6.84 per share$2.94 per share$6.64 per share$1.87 per share$0.85 per share
Price / Book1.566.34N/A6.425.98
Profitability
Net Income$-77,680,000.00$-77,190,000.00$-28,170,000.00$-75,440,000.00$31.88 million
EPS($1.95)($2.98)($4.80)($1.88)$0.30
Trailing P/E RatioN/AN/AN/AN/A12.70
Forward P/E RatioN/AN/AN/AN/A10.37
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-10,452.67%N/AN/A-1,950.42%36.09%
Return on Equity (ROE)-28.71%-103.21%N/A-84.15%52.28%
Return on Assets (ROA)-18.57%-56.14%N/A-50.21%42.40%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.06%0.25%0.02%0.58%0.01%
Current Ratio21.05%3.46%15.05%6.35%6.63%
Quick Ratio21.05%3.46%15.05%6.35%6.51%
Ownership Information
Institutional Ownership Percentage93.05%85.62%79.40%98.23%63.69%
Insider Ownership Percentage30.40%14.20%39.20%14.20%10.70%
Miscellaneous
Employees5964117651
Shares Outstanding39.91 million27.44 million17.39 million45.69 million103.42 million
Next Earnings Date8/4/2020 (Estimated)8/5/2020 (Estimated)8/11/2020 (Estimated)8/6/2020 (Estimated)8/5/2020 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableOptionable

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.